ID 1224 - Produkty o zmniejszonej zawartości laktozy

PL: Produkty o zmniejszonej zawartości laktozy
EN: Dairy with decrease/absence of lactose
Pdf:

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claim is lactose, which should be “decreased” or “reduced” in foods in order to obtain the claimed effect.
Lactose is a disaccharide of glucose and galactose and the primary sugar of mammalian milk. Lactose can be measured in foods by established methods.
The Panel considers that the food constituent, lactose, which is the subject of the health claim, is sufficiently characterised.

2. Znaczenie oświadczenia dla zdrowia człowieka

The claimed effects are “lactose intolerance”, “decrease lactose malabsorption symptoms” and “lactose digestion”. The Panel assumes that the target population is lactose intolerant individuals.
The Panel assumes that the claimed effects refer to decreasing gastro-intestinal discomfort caused by lactose intake in lactose intolerant individuals.
The Panel considers that decreasing gastro-intestinal discomfort caused by lactose intake in lactose intolerant individuals is a beneficial physiological effect for lactose intolerant individuals.

3. Naukowe uzasadnienia wpływu na zdrowie człowieka - Zmniejszenie dolegliwości żołądkowo-jelitowych spowodowanych spożyciem laktozy u osób z nietolerancją laktozy

Ingested lactose is hydrolysed by lactase (lactase-phlorizin hydrolase or LPH; EC 3.2.1.108), an enzyme of the microvillus membrane of the enterocytes. It is split into the monosaccharides glucose and galactose, which are rapidly and completely absorbed within the small intestine.
In adults with lactose maldigestion, undigested lactose reaches the colon where it is degraded to lactic acid, acetic acid, hydrogen and carbon dioxide by intestinal bacteria. Lactose maldigestion can elicit symptoms of lactose intolerance in some (but not all) lactose maldigesters.
Symptoms of lactose intolerance, which may develop one to three hours after lactase-deficient and lactose intolerant individuals ingest lactose in food, include abdominal pain, bloating, flatulence and diarrhoea. The clinical effects of lactose ingestion are closely related to the dose consumed and there is a wide variation among individuals regarding the dose-response. The only satisfactory dietary measure in lactose intolerance is a diet with reduced lactose content, and with individuals adapting their lactose consumption to their individual tolerance (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010).
The Panel concludes that a cause and effect relationship has been established between the consumption of lactose in amounts exceeding individual tolerances and the occurrence of symptoms of lactose intolerance in lactose intolerant individuals, and that consumption of foods with reduced lactose content may help to decrease gastro-intestinal discomfort caused by lactose intake in lactose intolerant individuals.

4. Uwagi do zaproponowanego brzmienia oświadczenia

The Panel considers that the following wording reflects the scientific evidence: “Consumption of lactose in amounts exceeding individual tolerances may lead to the occurrence of symptoms of lactose intolerance in lactose intolerant individuals; consumption of foods with reduced amounts of lactose may help to decrease gastro-intestinal discomfort caused by lactose intake in lactose intolerant individuals.”

5. Warunki i możliwe ograniczenia stosowania oświadczenia

The Panel considers that no single condition of use can be set because of the great variation in individual tolerances to lactose of lactose intolerant individuals (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2010).

Warunki i możliwe ograniczenia stosowania oświadczenia

Lactose consumption per product intake no more than 3 g